Page 6 - Read Online

Cancer Drug Resistance
CONTENTS

Topic: Targeted cancer therapy

Editorial

1 Targeted therapies in cancer: where are we going?
Elisa Giovannetti, Jose A. Rodriguez
Cancer Drug Resist 2018;1:82-6 http://dx.doi.org/10.20517/cdr.2018.05

Review

2 Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from
clinical trials
Xiaorong Wu, Thomas Kilpatrick, Ian Chau
Cancer Drug Resist 2018;1:204-18 http://dx.doi.org/10.20517/cdr.2018.16

3 Glutamine metabolism in cancer therapy
Tra-Ly Nguyen, Raúl V. Durán
Cancer Drug Resist 2018;1:126-38 http://dx.doi.org/10.20517/cdr.2018.08

4 Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic
approach in cancer
Maria Sendino, Miren Josu Omaetxebarria, Jose Antonio Rodríguez
Cancer Drug Resist 2018;1:139-63 http://dx.doi.org/10.20517/cdr.2018.09

5 Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents
Ilaria Genovese, Andrea Ilari, Theo Battista, Valerio Chiarini, Francesco Fazi, Annarita Fiorillo,
Gianni Colotti
Cancer Drug Resist 2018;1:164-80 http://dx.doi.org/10.20517/cdr.2018.10

6 Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Nele Van Der Steen, Elisa Giovannetti, Daniela Carbone, Alessandro Leonetti, Christian D. Rolfo,
Godefridus J. Peters
Cancer Drug Resist 2018;1:230-49 http://dx.doi.org/10.20517/cdr.2018.13

Opinion

7 Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis
and tumor therapeutic responses
Natalia J. Gurule, Lynn E. Heasley
Cancer Drug Resist 2018;1:118-25 http://dx.doi.org/10.20517/cdr.2018.12